Bradley W. Lash, MD

  • Clinical Details
  • Education
  • Clinical Trials
Hospital Privileges: 
  • Guthrie Corning Hospital
  • Guthrie Robert Packer Hospital
Clinical Interests: 
  • Gastroenterology cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Malignant and nonmalignant hematology
  • Melanoma
Certification: 
  • American Board of Internal Medicine
Education: 
  • SUNY Upstate Medical University, College of Medicine, Syracuse, N.Y.
Residency: 
  • Robert Packer Hospital, Sayre, Pa. (Internal Medicine)
Fellowship: 
  • The Lankenau Medical Center, Wynnewood, Pa. (Hematology/Medical Oncology)
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01150045
Title: CALGB 80702, A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01642251
Title: E2511, Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT00843882
Title: E2905, Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Indentifier #: NCT01169337
Title: E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01107626
Title: E5508, Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Golden Biotech
Indentifier #: NCT02047344
Title: GHNSCLC-2-001, A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients with Stage IV (including Pleural Effusion) Non-Squamous Non-Small Cell Lung Cancer (NSCLC) who have Failed Two Lines of Anti-Cancer Therapy
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Synta
Indentifier #: NCT01798485
Title: Galaxy-2 Trial; Protocol 9090-14: A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Adenocarcinoma
Department: Oncology
Diagnosis: Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: INC
Title: INCB-MA-PV-401, PROSPECTIVE, NON-INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES (REVEAL)
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01013649
Title: RTOG0848, A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Department: Oncology
Diagnosis: Head and Neck
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01810913
Title: RTOG 1216, Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01822496
Title: RTOG 1306, A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Indentifier #: NCT02154490
Title: S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Indentifier #: NCT01841736
Title: Alliance A021202, Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Indentifier #: NCT02438722
Title: SWOG S1403, A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Brain
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Indentifier #: NCT02152982
Title: Alliance A071102, A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Indentifier #: NCT02164916
Title: SWOG S1406, Randomized Phase II Study of Iri-notecan and Cetuximab with or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT00499330
Title: CALGB 140503 - A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2 cm) Peripheral Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01286272
Title: CALGB 50904, A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma
Department: Oncology
Diagnosis: Cancer Control
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01333033
Title:
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01642251
Title:
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT00843882
Title:
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Indentifier #: NCT01169337
Title:
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01107626
Title:
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Golden Biotech
Indentifier #: NCT02047344
Title:
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Synta
Indentifier #: NCT01798485
Title:
Department: Oncology
Diagnosis: Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: INC
Title:
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01013649
Title:
Department: Oncology
Diagnosis: Head and Neck
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01810913
Title:
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01822496
Title:
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Indentifier #: NCT02154490
Title:
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Indentifier #: NCT01841736
Title:
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT00499330
Title:
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01286272
Title:
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01150045
Title:
Department: Oncology
Diagnosis: Gastrointestinal - Liver
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01015833
Title:
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lash MD, Bradley
Sponsor: Pfizer
Indentifier #: NCT01525550
Title: A6181202, A Single Arm Open-Label International Multi Center Study Of The Efficacy And Safety Of Sunitinib Malate (SU011248, Sutent®) In Patients With Progressive Advanced Metastatic Well Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT00499330
Title: CALGB 140503 - A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2 cm) Peripheral Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01286272
Title: CALGB 50904, A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma
Department: Oncology
Diagnosis: Cancer Control
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01333033
Title: CALGB 80803,Randomized Phase II Trial of PET Scan-directed Combined Modality Therapy in Esophageal Cancer
Department: Oncology
Diagnosis: Genito-urinary - Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT00942331
Title: CALGB-90601 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, And Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: CTSU -NCI
Indentifier #: NCT00588770
Title: E1305, A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01642251
Title: E2511, Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01107626
Title: E5508, Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Indentifier #: NCT00828009
Title: E6508, A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01822496
Title: RTOG 1306, A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Indentifier #: NCT02154490
Title: S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Indentifier #: NCT01841736
Title: Alliance A021202, Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors; ClinicalTrials.gov identifier: NCT01841736
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Indentifier #: NCT01841736
Title: Alliance A021202, Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors; ClinicalTrials.gov identifier: NCT01841736
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lash MD, Bradley
Sponsor: Pfizer
Indentifier #: NCT01525550
Title: A6181202, A Single Arm Open-Label International Multi Center Study Of The Efficacy And Safety Of Sunitinib Malate (SU011248, Sutent®) In Patients With Progressive Advanced Metastatic Well Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT00499330
Title: CALGB 140503 - A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2 cm) Peripheral Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01286272
Title: CALGB 50904, A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma
Department: Oncology
Diagnosis: Cancer Control
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01333033
Title: CALGB 80803,Randomized Phase II Trial of PET Scan-directed Combined Modality Therapy in Esophageal Cancer
Department: Oncology
Diagnosis: Genito-urinary - Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT00942331
Title: CALGB-90601 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, And Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: CTSU -NCI
Indentifier #: NCT00588770
Title: E1305, A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01642251
Title: E2511, Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01107626
Title: E5508, Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Indentifier #: NCT00828009
Title: E6508, A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Indentifier #: NCT01822496
Title: RTOG 1306, A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Indentifier #: NCT02154490
Title: S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer